Results from Alliance CABOSUN trial lead to US FDA approval of extended indication

(Alliance for Clinical Trials in Oncology) The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news